405 related articles for article (PubMed ID: 21827408)
1. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected.
Löscher W; Luna-Tortós C; Römermann K; Fedrowitz M
Curr Pharm Des; 2011; 17(26):2808-28. PubMed ID: 21827408
[TBL] [Abstract][Full Text] [Related]
2. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
3. ABC Transporters and Drug Resistance in Patients with Epilepsy.
Feldmann M; Koepp M
Curr Pharm Des; 2016; 22(38):5793-5807. PubMed ID: 27514707
[TBL] [Abstract][Full Text] [Related]
4. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
[TBL] [Abstract][Full Text] [Related]
5. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
6. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.
Löscher W; Potschka H
J Pharmacol Exp Ther; 2002 Apr; 301(1):7-14. PubMed ID: 11907151
[TBL] [Abstract][Full Text] [Related]
7. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy.
Lazarowski A; Czornyj L; Lubienieki F; Girardi E; Vazquez S; D'Giano C
Epilepsia; 2007; 48 Suppl 5():140-9. PubMed ID: 17910594
[TBL] [Abstract][Full Text] [Related]
8. Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.
Bankstahl M; Klein S; Römermann K; Löscher W
Neuropharmacology; 2016 Oct; 109():183-195. PubMed ID: 27288003
[TBL] [Abstract][Full Text] [Related]
9. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.
Potschka H; Fedrowitz M; Löscher W
Neurosci Lett; 2002 Jul; 327(3):173-6. PubMed ID: 12113905
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2010 Jun; 58(7):1019-32. PubMed ID: 20080116
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.
Hoffmann K; Löscher W
Epilepsia; 2007 Apr; 48(4):631-45. PubMed ID: 17437408
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.
Potschka H; Baltes S; Löscher W
Epilepsy Res; 2004 Feb; 58(2-3):85-91. PubMed ID: 15120740
[TBL] [Abstract][Full Text] [Related]
13. Potential role for human P-glycoprotein in the transport of lacosamide.
Zhang C; Chanteux H; Zuo Z; Kwan P; Baum L
Epilepsia; 2013 Jul; 54(7):1154-60. PubMed ID: 23551115
[TBL] [Abstract][Full Text] [Related]
14. A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives.
Langeh U; Chawla P; Gupta GD; Singh S
CNS Neurol Disord Drug Targets; 2020; 19(10):741-749. PubMed ID: 32814543
[TBL] [Abstract][Full Text] [Related]
15. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
[TBL] [Abstract][Full Text] [Related]
16. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins.
Luna-Tortós C; Rambeck B; Jürgens UH; Löscher W
Pharm Res; 2009 Nov; 26(11):2464-70. PubMed ID: 19730994
[TBL] [Abstract][Full Text] [Related]
17. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein.
Zhang C; Zuo Z; Kwan P; Baum L
Epilepsia; 2011 Oct; 52(10):1894-904. PubMed ID: 21692796
[TBL] [Abstract][Full Text] [Related]
18. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy.
Marroni M; Marchi N; Cucullo L; Abbott NJ; Signorelli K; Janigro D
Curr Drug Targets; 2003 May; 4(4):297-304. PubMed ID: 12699350
[TBL] [Abstract][Full Text] [Related]
19. Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy.
Williams S; Hossain M; Ferguson L; Busch RM; Marchi N; Gonzalez-Martinez J; Perucca E; Najm IM; Ghosh C
Mol Neurobiol; 2019 Dec; 56(12):8392-8407. PubMed ID: 31243719
[TBL] [Abstract][Full Text] [Related]
20. Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.
Löscher W; Langer O
Curr Top Med Chem; 2010; 10(17):1785-91. PubMed ID: 20645916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
